Patient's Perspective in Clinical Practice to Assess and Predict Disability in Multiple Sclerosis

Overview

Journal Sci Rep

Specialty Science

Date 2022 Oct 30

PMID 36309532

Authors

S Gil-Perotin

L Bernad

S Reddam

C Ferrer-Pardo

S Navarro-Quevedo

L Solis-Tarazona

Affiliations

Soon will be listed here.

Abstract

The information provided by a person with multiple sclerosis (MS) may anticipate changes in the course of the disease. To explore the role of a set of standardized patient-reported outcomes (PRO) in predicting disability progression in MS an observational study was conducted in two cohorts of 30 and 86 persons with progressive MS (pwPMS) and relapsing MS (pwRMS), respectively. The associations between baseline clinical, biochemical variables and results on MS quality of life scale (MusiQol), Modified Fatigue Impact Scale (MFIS) and Beck Depression Inventory II (BDI-II) were analyzed. The progression of disability after 2 years of follow-up in pwRMS was investigated. We show that PRO differentiated pwRMS and pwPMS cohorts with lower MusiQoL and higher MFIS and BDI-II scores in the latter. Only MFIS was correlated with disability in pwRMS and high scores in the physical MFIS domain associated with worse performance in 9HPT, and a trend in T25FW and SDMT. Instead, the cognitive MFIS domain was correlated with CHI3L1 in cerebrospinal fluid, a biomarker of progression. At the end of the study, global MFIS and BDI-II were found to be independent risk factors for disability independent of relapse. Although all PRO measures explored were altered in pwPMS, baseline MFIS discriminated current and prospective disability in pwRMS, identifying patients at risk of progression.

References

Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S . Multiple sclerosis. Nat Rev Dis Primers. 2018; 4(1):43. DOI: 10.1038/s41572-018-0041-4. View

Marchesi O, Vizzino C, Meani A, Conti L, Riccitelli G, Preziosa P . Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. Eur J Neurol. 2020; 27(12):2549-2560. DOI: 10.1111/ene.14471. View

Thompson A, Banwell B, Barkhof F, Carroll W, Coetzee T, Comi G . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2017; 17(2):162-173. DOI: 10.1016/S1474-4422(17)30470-2. View

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

Al Jumah M, Kojan S, Alroughani R, Cupler E, Bohlega S, Daif A . A Prospective Multicenter Study for Assessing MusiQoL Validity among Arabic-Speaking MS Patients Treated with Subcutaneous Interferon -1a. Mult Scler Int. 2021; 2021:6681431. PMC: 7943271. DOI: 10.1155/2021/6681431. View

Mitchell A, Benito-Leon J, Gonzalez J, Rivera-Navarro J . Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing. Lancet Neurol. 2005; 4(9):556-66. DOI: 10.1016/S1474-4422(05)70166-6. View

Ghajarzadeh M, Jalilian R, Eskandari G, Sahraian M, Azimi A, Mohammadifar M . Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex. Acta Neurol Belg. 2013; 113(4):411-4. DOI: 10.1007/s13760-013-0198-2. View

Farran N, Safieddine B, Bayram M, Abi Hanna T, Massouh J, AlKhawaja M . Factors affecting MS patients' health-related quality of life and measurement challenges in Lebanon and the MENA region. Mult Scler J Exp Transl Clin. 2020; 6(1):2055217319848467. PMC: 6956607. DOI: 10.1177/2055217319848467. View

Reese J, Wienemann G, John A, Linnemann A, Balzer-Geldsetzer M, Mueller U . Preference-based Health status in a German outpatient cohort with multiple sclerosis. Health Qual Life Outcomes. 2013; 11:162. PMC: 3851447. DOI: 10.1186/1477-7525-11-162. View

10.

Zhang Y, Taylor B, Simpson Jr S, Blizzard L, van der Mei I . Patient-reported outcomes are worse for progressive-onset multiple sclerosis than relapse-onset multiple sclerosis, particularly early in the disease process. Eur J Neurol. 2018; 26(1):155-161. DOI: 10.1111/ene.13786. View

11.

Healy B, Zurawski J, Chitnis T, Weiner H, Glanz B . Patient-reported outcomes associated with transition to secondary progressive multiple sclerosis. Qual Life Res. 2021; 31(6):1799-1805. DOI: 10.1007/s11136-021-03034-6. View

12.

Gil-Perotin S, Castillo-Villalba J, Cubas-Nunez L, Gasque R, Hervas D, Gomez-Mateu J . Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis. Front Neurol. 2019; 10:1008. PMC: 6768010. DOI: 10.3389/fneur.2019.01008. View

13.

Hakansson I, Johansson L, Dahle C, Vrethem M, Ernerudh J . Fatigue scores correlate with other self-assessment data, but not with clinical and biomarker parameters, in CIS and RRMS. Mult Scler Relat Disord. 2019; 36:101424. DOI: 10.1016/j.msard.2019.101424. View

14.

Confavreux C, Vukusic S . Natural history of multiple sclerosis: a unifying concept. Brain. 2006; 129(Pt 3):606-16. DOI: 10.1093/brain/awl007. View

15.

Bakshi R, Shaikh Z, Miletich R, Czarnecki D, Dmochowski J, Henschel K . Fatigue in multiple sclerosis and its relationship to depression and neurologic disability. Mult Scler. 2000; 6(3):181-5. DOI: 10.1177/135245850000600308. View

16.

Floro S, Carandini T, Pietroboni A, De Riz M, Scarpini E, Galimberti D . Role of Chitinase 3-like 1 as a Biomarker in Multiple Sclerosis: A Systematic Review and Meta-analysis. Neurol Neuroimmunol Neuroinflamm. 2022; 9(4). PMC: 9128043. DOI: 10.1212/NXI.0000000000001164. View

17.

Cubas-Nunez L, Gil-Perotin S, Castillo-Villalba J, Lopez V, Solis Tarazona L, Gasque-Rubio R . Potential Role of CHI3L1+ Astrocytes in Progression in MS. Neurol Neuroimmunol Neuroinflamm. 2021; 8(3). PMC: 7931642. DOI: 10.1212/NXI.0000000000000972. View

18.

Baumstarck K, Butzkueven H, Fernandez O, Flachenecker P, Stecchi S, Idiman E . Responsiveness of the Multiple Sclerosis International Quality of Life questionnaire to disability change: a longitudinal study. Health Qual Life Outcomes. 2013; 11:127. PMC: 3735484. DOI: 10.1186/1477-7525-11-127. View

19.

Krajnc N, Bsteh G, Berger T . Clinical and Paraclinical Biomarkers and the Hitches to Assess Conversion to Secondary Progressive Multiple Sclerosis: A Systematic Review. Front Neurol. 2021; 12:666868. PMC: 8427301. DOI: 10.3389/fneur.2021.666868. View

20.

Palotai M, Small C, Makris N, Somes N, Pinzon A, Rathi Y . Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis. J Neuroimaging. 2021; 31(3):501-507. PMC: 8119307. DOI: 10.1111/jon.12832. View